Eledon Pharmaceuticals, Inc. (ELDN)
NASDAQ: ELDN · Real-Time Price · USD
1.580
-0.010 (-0.63%)
At close: Dec 5, 2025, 4:00 PM EST
1.610
+0.030 (1.90%)
After-hours: Dec 5, 2025, 6:51 PM EST
Eledon Pharmaceuticals Employees
Eledon Pharmaceuticals had 31 employees as of December 31, 2024. The number of employees increased by 11 or 55.00% compared to the previous year.
Employees
31
Change (1Y)
11
Growth (1Y)
55.00%
Revenue / Employee
n/a
Profits / Employee
-$2,666,742
Market Cap
118.74M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ELDN News
- 5 days ago - Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference - GlobeNewsWire
- 17 days ago - Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine - GlobeNewsWire
- 18 days ago - Eledon Pharmaceuticals, Inc. (ELDN) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript - Seeking Alpha
- 21 days ago - Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results - GlobeNewsWire
- 24 days ago - Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 24 days ago - Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 4 weeks ago - Eledon Pharmaceuticals, Inc. (ELDN) Discusses Phase II BESTOW Trial Results and Advances in Transplantation Immunosuppression Transcript - Seeking Alpha
- 4 weeks ago - Eledon Pharmaceuticals' Lead Asset Fails In Mid-Stage Study, But Pushes Forward With Pivotal Study - Benzinga